Clinical Trials Browser

Completed × INDUSTRY × Trabedersen × Clear all

NCT00844064 2019-02-15

Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2

Phase 1 Completed

DermatologicGastrointestinal

Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

NCT00431561 2013-12-03

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Phase 2 Completed

Astrocytoma, Brain Neoplasms, Camurati-Engelmann Syndrome, Glioblastoma, Neoplasms